Taken together, our data indicate that RNF183 contributes to the transformation from inflammation to malignancy in CRC, and predicts the application of NF-κB inhibitors or IL-8 antagonists for precision therapy of CRC with elevated RNF183 expression. The gene discussed is CXCL8; the disease is colorectal carcinoma.